Novo Nordisk and Eli Lilly are competing in the obesity drug market with their GLP-1 pills, Wegovy and Foundayo, respectively. Both companies are preparing for Medicare to cover these drugs for weight loss at $50 per month starting July 1, which could expand access to millions of seniors. Novo Nordisk has seen over 3 million prescriptions for Wegovy since its U.S. launch five months ago, while Lilly reports rapidly increasing prescriptions of Foundayo. The companies emphasize different benefits: Novo highlights additional cardiovascular and organ protection, while Lilly promotes convenience and ease of use. Both are also developing next-generation obesity drugs, with Lilly advancing retatrutide and Novo working on CagriSema, aiming to maintain leadership in the growing obesity treatment market.
Novo Nordisk announced positive Phase 3 trial results for CagriSema, a once-weekly therapy combining an amylin analog with a GLP-1 receptor agonist, which significantly reduced HbA1c and body weight in adults with Type 2 diabetes. The company also sh...
Novo Nordisk initiated a share repurchase program starting 4 February 2026, aiming to buy back up to DKK 15 billion worth of B shares within 12 months. As of early June 2026, the company has repurchased over 18.7 million B shares at an average price ...
The Wegovy pill, a GLP-1 weight-loss medication by Novo Nordisk, has surpassed 3 million prescriptions in the US since its launch on January 5, 2026. This equates to one prescription filled every five seconds, marking it as one of the most successful...
This monthly series highlights five large-cap, dividend-paying stocks trading at significant discounts compared to their historical norms, selected from over 7,500 U.S.-listed companies. The primary list offers an average yield of 4.2%, with two addi...
The 4-Factor Dividend Growth Strategy, inspired by the Schwab US Dividend Equity ETF (SCHD), targets high-quality dividend stocks using four specific metrics. Since its inception, it has delivered an average 12-month return of 16.94%, outperforming S...
